Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
Author(s) -
Bruce C. Trapnell,
Yoshikazu Inoue,
Francesco Bonella,
Cliff Morgan,
S. Jouneau,
Elisabeth Bendstrup,
Ilaria Campo,
Spyros A. Papiris,
Etsuro Yamaguchi,
Erdoğan Çetınkaya,
M. M. Ilkovich,
Mordechai R. Kramer,
Marcel Veltkamp,
Michael Kreuter,
Tomohisa Baba,
Cecilia Ganslandt,
Inge Tarnow,
Grant Waterer,
Taneli Jouhikainen
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1913590
Subject(s) - medicine , placebo , inhalation , pulmonary alveolar proteinosis , randomization , anesthesia , clinical endpoint , clinical trial , surgery , lung , pathology , alternative medicine
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia. It is caused by disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, which pulmonary alveolar macrophages require to clear surfactant. Recently, inhaled GM-CSF was shown to improve the partial pressure of arterial oxygen in patients with aPAP.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom